Synektik (SNTP) Q1 2026 earnings summary

Executive summary

• Achieved 12% year-over-year growth in total revenue to 228.0 million PLN for Q1 FY2025, with strong performance in medical equipment, IT solutions, and radio-pharmaceuticals segments.

• EBITDA from continuing operations rose 18% year-over-year to 59.8 million PLN, and net profit from continuing operations increased 18% to 43.1 million PLN.

• Significant progress in recurring revenue, up 34% year-over-year to 91.2 million PLN, driven by service contracts and consumables.

• Strategic expansion in robotic surgery and IT, including new distribution agreements and market entry plans for Ukraine.

Financial highlights

• Revenue: 227.98 million PLN (Q1 FY2025) vs. 203.13 million PLN (Q1 FY2024), up 12%.

• EBITDA (continuing): 59.8 million PLN, up 18% year-over-year.

• Net profit (continuing): 43.1 million PLN, up 18% year-over-year.

• Radio-pharmaceuticals segment revenue: 13.9 million PLN, up 15% year-over-year.

• Recurring revenue (last 12 months): 334.3 million PLN, up 52% year-over-year.

Outlook and guidance

• Management expects continued growth in medical equipment and IT services, supported by public healthcare investments and EU funds.

• Expansion in robotic surgery, including new markets (Ukraine), and introduction of new products like the Edison system.

• Ongoing development of the cardiomarker project and clinical research activities.